CA-ASM-GLOBAL
The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/
PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire)
ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of 2025’s formal unveiling.
The project will include a 50,000-capacity main stadium with the theme “Pearl of the Orient” as its design inspiration and boasting a retractable roof and flexible pitch surface that can host a wide range of events in any weather, including major sports events, concerts and MICE events; a 10,000-capacity indoor sports arena that meets the standard of major international tournaments for a wide range of athletics, including basketball, tennis, gymnastics, family shows and other entertainment events; a 5,000-spectator, open-to-the-public sports ground for hosting school sports days, athletic meets, local football and rugby matches as well as team and athlete training sessions; and an outdoor recreation complex.
ASM Global’s President and CEO Ron Bension said, “ASM Global develops and builds spectacular venues and extraordinary entertainment districts throughout the world; but nothing compares to the scale, scope and state-of-the art innovation of Kai Tak.”
The Hong Kong site is part of ASM Global’s network of more than 400 venues around the world. The company works with major cultural and entertainment districts and venues and projects throughout the world, including Darling Harbour in Sydney, OVO Arena Wembley in London, AO Arena in Manchester and Desert Diamond in Arizona.
Officials said the expansive development will set the benchmark for multipurpose sports precincts worldwide, integrating the most advanced sports facilities with retail, wellness and community leisure spaces to create an urban oasis for the 7.4 million local community and millions of overseas visitors.
KTSPL, when awarded the contract for the design, build, construction and operation of the Kai Tak Sports Park, subsequently assembled an unparalleled project team comprising overseas and local experts in design; retail sales and marketing; construction led by Hip Hing; and ASM Global for project management, premium sales and programming.
The precinct is designed around the one-of-a-kind Kai Tak Sports Avenue. This indoor and outdoor pedestrian walk starts at Station Square and transports people completely through the immense site.
Throughout the complex will be restaurants, retail shops, jogging trails, a health and wellness center, as well as an international-standard bowling center with 40 lanes suitable for hosting international tournaments and a climbing wall on Sports Avenue.
ASM Global and KTSPL’s state-of-the-art environmentally conscious design decisions are critical to the project, intended to set and meet measurable goals to reduce impacts on the planet and champion dynamic programs for the longevity and well-being of the local community.
The focus of these sustainability efforts includes integration of photovoltaic panels on all major facilities, extensive green roofscapes and an expansive network of electric charging stations across the precinct. Smart city initiatives include an intelligent building and car management system, Wi-Fi hotspots, an indoor positioning system and mobile applications to facilitate precinct information booking of facilities and wayfinding.
Kai Tak Sports Park is expected to formally open in early 2025 and is one of the sports venues that will deliver events for the 2025 15th National Games of China that is being hosted in the Greater Bay Area.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom